These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 18471139)

  • 41. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract.
    Liu Q; Yang Q; Sun W; Vogel P; Heydorn W; Yu XQ; Hu Z; Yu W; Jonas B; Pineda R; Calderon-Gay V; Germann M; O'Neill E; Brommage R; Cullinan E; Platt K; Wilson A; Powell D; Sands A; Zambrowicz B; Shi ZC
    J Pharmacol Exp Ther; 2008 Apr; 325(1):47-55. PubMed ID: 18192499
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Probable mechanisms of the regulation in the jejunum motility].
    Lychkova AE; Savchuk VI; Smirnov VM; Trubitsyna IE
    Eksp Klin Gastroenterol; 2003; (6):121-2, 155. PubMed ID: 15065541
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Agonists and antagonists of 5-hydroxytryptamine on venomotor receptors.
    Aellig WH
    Adv Neurol; 1982; 33():321-4. PubMed ID: 7055012
    [No Abstract]   [Full Text] [Related]  

  • 44. Modulation of anxiety circuits by serotonergic systems.
    Lowry CA; Johnson PL; Hay-Schmidt A; Mikkelsen J; Shekhar A
    Stress; 2005 Dec; 8(4):233-46. PubMed ID: 16423712
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New insights into the pathophysiology of IBS: intestinal microflora, gas production and gut motility.
    Gasbarrini A; Lauritano EC; Garcovich M; Sparano L; Gasbarrini G
    Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():111-7. PubMed ID: 18924450
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent advances in understanding the role of serotonin in gastrointestinal motility and functional bowel disorders.
    Galligan JJ; Parkman H
    Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2():1-4. PubMed ID: 17620081
    [No Abstract]   [Full Text] [Related]  

  • 47. Mechanisms of serotonergic agents for treatment of gastrointestinal motility and functional bowel disorders.
    Kindt S; Tack J
    Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2():32-9. PubMed ID: 17620086
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
    Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
    Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Tegaserod].
    Häusser-Fruh G
    Krankenpfl J; 2000 Oct; 38(9-10):337-8. PubMed ID: 11194352
    [No Abstract]   [Full Text] [Related]  

  • 50. Serotoninergic mechanisms of immunomodulation under different psychoemotional states: I. A role of 5-HT 1A receptor subtype.
    Idova G; Davydova S; Alperina E; Cheido M; Devoino L
    Int J Neurosci; 2008 Nov; 118(11):1594-608. PubMed ID: 18853336
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse.
    Bubar MJ; Cunningham KA
    Prog Brain Res; 2008; 172():319-46. PubMed ID: 18772040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Serotonin syndrome].
    Lheureux P; Penaloza A; De Cottenier V; Ullmann U; Gris M
    Rev Med Brux; 2002 Oct; 23(5):422-8. PubMed ID: 12474323
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies.
    Di Matteo V; Di Giovanni G; Pierucci M; Esposito E
    Prog Brain Res; 2008; 172():7-44. PubMed ID: 18772026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.
    Muñoz A; Carlsson T; Tronci E; Kirik D; Björklund A; Carta M
    Exp Neurol; 2009 Sep; 219(1):298-307. PubMed ID: 19500572
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Gastrointestinal motility disorders and drugs: opioids, calcium antagonists, nitrates, peptides, prostaglandins and 5-hydroxytryptaminergic drugs (part II)].
    Jovanović-Mićić D; Samardzić R; Beleslin B
    Srp Arh Celok Lek; 1994; 122(3-4):88-92. PubMed ID: 17972818
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic implications of modifying endogenous serotonergic analgesic systems.
    Frier JW
    Anesth Prog; 1985; 32(1):19-22. PubMed ID: 2986489
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 5-Hydroxytryptamine: new receptors and novel drugs for gastrointestinal motor disorders.
    Costall B; Naylor RJ
    Scand J Gastroenterol; 1990 Aug; 25(8):769-87. PubMed ID: 2205896
    [No Abstract]   [Full Text] [Related]  

  • 58. Serotonin and GI clinical disorders.
    Spiller R
    Neuropharmacology; 2008 Nov; 55(6):1072-80. PubMed ID: 18687345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The world of serotonin and its receptors. Physiopathologic, clinical, and therapeutic aspects].
    Marco Igual M
    Med Clin (Barc); 1993 Jun; 101(4):144-53. PubMed ID: 8355545
    [No Abstract]   [Full Text] [Related]  

  • 60. Importance of 5-hydroxytryptamine receptors on intestinal afferents in the regulation of visceral sensitivity.
    Greenwood-van Meerveld B
    Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2():13-8. PubMed ID: 17620083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.